These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 10610578)
1. MTA, A Novel Multitargeted Antifolate: from preclinical to phase I and beyond. Proceedings of a meeting. Ixtapa, Mexico, March 13-15, 1998. Semin Oncol; 1999 Apr; 26(2 Suppl 6):1-110. PubMed ID: 10610578 [No Abstract] [Full Text] [Related]
2. MTA, a novel multitargeted antifolate, from preclinical to phase I and beyond: summary and conclusions. Calvert H Semin Oncol; 1999 Apr; 26(2 Suppl 6):105-8. PubMed ID: 10598564 [No Abstract] [Full Text] [Related]
3. Antifolates: the next millennium. Allegra CJ Semin Oncol; 1999 Apr; 26(2 Suppl 6):1-2. PubMed ID: 10598548 [No Abstract] [Full Text] [Related]
4. An overview of folate metabolism: features relevant to the action and toxicities of antifolate anticancer agents. Calvert H Semin Oncol; 1999 Apr; 26(2 Suppl 6):3-10. PubMed ID: 10598549 [No Abstract] [Full Text] [Related]
5. Pemetrexed, an novel multitargeted antifolate: current development and future directions. Proceedings of a meeting. August 17-19, 2000. Colorado Springs, Colorado, USA. Semin Oncol; 2002 Apr; 29(2 Suppl 5):1-61; quiz 62-9. PubMed ID: 12023785 [No Abstract] [Full Text] [Related]
6. Pemetrexed: a multitargeted antifolate (ALIMTA, LY-231514). Jones RJ; Twelves CJ Expert Rev Anticancer Ther; 2002 Feb; 2(1):13-22. PubMed ID: 12113062 [TBL] [Abstract][Full Text] [Related]
7. Overview of phase I trials of multitargeted antifolate (MTA, LY231514). Rinaldi DA Semin Oncol; 1999 Apr; 26(2 Suppl 6):82-8. PubMed ID: 10598560 [TBL] [Abstract][Full Text] [Related]
12. Prevention of thymidine and hypoxanthine rescue from MTA (LY231514) growth inhibition by dipyridamole in human lung cancer cell lines. Smith PG; Marshman E; Calvert AH; Newell DR; Curtin NJ Semin Oncol; 1999 Apr; 26(2 Suppl 6):63-7. PubMed ID: 10598557 [TBL] [Abstract][Full Text] [Related]
13. Overview of phase II trials of MTA in solid tumors. O'Dwyer PJ; Nelson K; Thornton DE Semin Oncol; 1999 Apr; 26(2 Suppl 6):99-104. PubMed ID: 10598563 [TBL] [Abstract][Full Text] [Related]
15. The role of pemetrexed in the treatment of colorectal cancer. Hochster H Semin Oncol; 2002 Dec; 29(6 Suppl 18):54-6. PubMed ID: 12571812 [TBL] [Abstract][Full Text] [Related]
16. Effect of folic acid and vitamin B12 on pemetrexed antifolate chemotherapy in nutrient lung cancer cells. Yang TY; Chang GC; Hsu SL; Huang YR; Chiu LY; Sheu GT Biomed Res Int; 2013; 2013():389046. PubMed ID: 23984356 [TBL] [Abstract][Full Text] [Related]
17. Pemetrexed: a multitargeted antifolate agent with promising activity in solid tumors. Adjei AA Ann Oncol; 2000 Oct; 11(10):1335-41. PubMed ID: 11106124 [TBL] [Abstract][Full Text] [Related]
18. Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs. Schultz RM; Chen VJ; Bewley JR; Roberts EF; Shih C; Dempsey JA Semin Oncol; 1999 Apr; 26(2 Suppl 6):68-73. PubMed ID: 10598558 [TBL] [Abstract][Full Text] [Related]
19. Cellular pharmacology of MTA: a correlation of MTA-induced cellular toxicity and in vitro enzyme inhibition with its effect on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells. Chen VJ; Bewley JR; Andis SL; Schultz RM; Iversen PW; Shih C; Mendelsohn LG; Seitz DE; Tonkinson JL Semin Oncol; 1999 Apr; 26(2 Suppl 6):48-54. PubMed ID: 10598555 [TBL] [Abstract][Full Text] [Related]